Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $43.25 Average Price Target from Brokerages

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $43.25.

A number of research analysts recently issued reports on ARWR shares. B. Riley reiterated a “buy” rating and set a $55.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Finally, Chardan Capital reiterated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 17th.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $18.82 on Thursday. Arrowhead Pharmaceuticals has a 12 month low of $18.15 and a 12 month high of $39.83. The stock’s 50-day moving average is $22.80 and its 200-day moving average is $24.56. The company has a market cap of $2.34 billion, a price-to-earnings ratio of -4.43 and a beta of 0.95.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 152.95%. During the same quarter last year, the business earned ($0.96) EPS. The business’s revenue was down 100.0% compared to the same quarter last year. Research analysts anticipate that Arrowhead Pharmaceuticals will post -4.31 EPS for the current year.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Fifth Third Bancorp grew its stake in shares of Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 354 shares during the last quarter. Neo Ivy Capital Management bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $41,000. Headlands Technologies LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 7,696.8% in the 1st quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 2,386 shares in the last quarter. Meeder Asset Management Inc. raised its position in Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after buying an additional 3,333 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in Arrowhead Pharmaceuticals in the second quarter worth approximately $96,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.